{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-403481","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2026-09-28T12:53:56+00:00","discovered_at":"2026-09-28T12:55:00.713639+00:00","generated_at":"2026-10-12T13:32:26.501872+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Kodiak's Zenkuda, tabirafusp-ted hit primary endpoints in Phase 3 DAYBREAK wAMD trial; Zenkuda BLA set for 4Q2026","bullets":["Zenkuda (tarcocimab tedromer) met the vision primary endpoint with p=0.0007; 54% of patients maintained 24-week dosing at year one under strict treat-to-dryness retreatment criteria.","Tabirafusp-ted (KSI-501) met the vision primary endpoint (p=0.0036) and the anatomical key secondary endpoint (p<0.0001); both agents achieved non-inferiority vs aflibercept at year one.","Zenkuda safety: 0% intraocular inflammation and 0.5% cataract rate (vs 0.9% for aflibercept); tabirafusp-ted showed 0.4% inflammation and 0% cataract.","Kodiak plans a multi-indication Zenkuda BLA in 4Q2026 backed by five positive Phase 3 studies: DAYBREAK and DAYLIGHT (wAMD), GLOW and GLOW2 (diabetic retinopathy), BEACON (RVO).","KSI-101 Phase 3 topline in macular edema secondary to inflammation (MESI) expected December 2026; tabirafusp-ted advancing in the Phase 3 ALTO program for diabetic macular edema."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-403481","json":"https://secwatch.observer/filing/0001193125-26-403481.json","markdown":"https://secwatch.observer/filing/0001193125-26-403481.md","text":"https://secwatch.observer/filing/0001193125-26-403481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000119312526403481/0001193125-26-403481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000119312526403481/d185059d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:32:26.501872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}